OTCMKTS:CRXM Gene Biotherapeutics (CRXM) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free CRXM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Gene Biotherapeutics alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Gene Biotherapeutics Stock (OTCMKTS:CRXM)Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… CRXM Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comTCI Gene Enhancing Malaysia's Preventive Healthcare In Collaboration With ALPRO PharmacyMarch 28, 2024 | msn.comAll lanes closed after crash on Gene Snyder FreewayMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | msn.comGene Wilder’s Last Words Have Finally Been RevealedMarch 27, 2024 | msn.comGene therapy maker bluebird to revise financials after accounting errorsMarch 27, 2024 | msn.comGene Simmons promises 'no more makeup' as Kiss rocker embarks on solo careerMarch 27, 2024 | msn.comKiss’ Gene Simmons Is Promising ‘No More Make-Up’March 27, 2024 | msn.comGene's RestaurantMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | msn.com'No more make-up': Gene Simmons makes pledge ahead of solo showsMarch 26, 2024 | reuters.comGene therapy maker bluebird to restate 2022 financials after accounting errorMarch 26, 2024 | msn.comGene Simmons on First Solo Band Shows Since KISS Farewell Tour: 'No More Makeup for Me' (Exclusive)March 25, 2024 | msn.comMel Brooks Was ‘Inconsolable’ After Gene Wilder’s DeathMarch 23, 2024 | msn.comMel Brooks' Heartache Over Gene Wilder's Alzheimer's StruggleMarch 23, 2024 | msn.comGene Wilder's death after Alzheimer's battle left Mel Brooks 'inconsolable,' filmmaker remembersMarch 23, 2024 | msn.comGene Byte Private Limited Helps PTE Core Test Preparation with AI-based SoftwareMarch 22, 2024 | msn.comMr. Gene’s Beans - Fairhope, AlabamaMarch 22, 2024 | yahoo.comGene Kelly Movies: The Musicals That Made the Multitalented Charmer Hollywood RoyaltyMarch 22, 2024 | msn.comWhy is Gene Steratore on March Madness broadcasts? Explaining ex-NFL referee's college basketball backgroundMarch 22, 2024 | msn.comSurgeons Transplant Gene-Edited Pig Kidney Into a Living PatientMarch 22, 2024 | msn.comThe Time Roger Ebert and Gene Siskel Stood Up For Star WarsMarch 21, 2024 | msn.comGene Smith honored with special 'Buckeye Award'March 21, 2024 | msn.comPatient Walking Around Hospital After Transplant of Gene-Hacked Pig KidneyMarch 21, 2024 | yahoo.comGene Kelly’s widow says she never ‘thought’ about 47-year age gapMarch 21, 2024 | msn.comGeorge Strait Mourns Death of Longtime Band Member Gene Elders: ‘We Loved Him So Much’March 21, 2024 | msn.comGene-edited pig kidney transplanted in human successfullyMarch 21, 2024 | msn.comGene Munster Agrees With Dan Nathan's Views That These 2 Magnificent 7 Companies Are AI Underdogs: 'I Believe That Will Change'See More Headlines Receive CRXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXM Previous SymbolNYSE:CXM CUSIPN/A CIK772320 Webwww.cardiumthx.com Phone(858) 414-1477Fax858-436-1001Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Christopher J. Reinhard (Age 70)Co-Founder, CEO, President, Treasurer & Director Comp: $240kMr. James L. Grainer (Age 69)Chairman, CFO & Secretary Dr. Lois A. Chandler (Age 66)Chief Operating Officer Dr. Ronald J. Shebuski (Age 71)Chief Scientific Officer Mr. Duane LinstromGeneral CounselKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAlvotechNYSE:ALVOAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQEnzon PharmaceuticalsOTCMKTS:ENZNView All Competitors CRXM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Gene Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Intellipharmaceutics International (IPCIF), MGT Capital Investments (MGTI) and Nokia Oyj (NOK). How do I buy shares of Gene Biotherapeutics? Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRXM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gene Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.